November 17, 2011 -- Two years ago, Carl Firth, PhD, MBA, was scrutinizing the possibilities implicit in Asia’s drug development scene. That led Firth to a very non-rhetorical question: “What can we do to leverage all these high quality assets?” he asked. The answer to that question is ASLAN Pharmaceuticals, a Singapore-based drug development startup with a virtual business model. In its first 18 months, ASLAN has completed its first round of fund raising, in-licensed two drug candidates, and Dr. Firth told ChinaBio® Today in an exclusive interview that a third deal will be announced soon. More details....
